Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02453282 · ClinicalTrials.gov registry record · Phase 3

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

A Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,118
Enrollment target
20
Study locations

NCT02453282: Active Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca.

NCT02453282 is a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,118 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02453282, a Phase 3 study of Non-Small-Cell Lung Carcinoma NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,118 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Primary Outcome

The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique.

Conditions Studied

Non-Small-Cell Lung Carcinoma NSCLC

Interventions

  • BIOLOGICAL MEDI4736 (Durvalumab)
  • BIOLOGICAL MEDI4736 (Durvalumab)+Tremelimumab
  • DRUG Paclitaxel + Carboplatin
  • DRUG Gemcitabine + Cisplatin
  • DRUG Gemcitabine + Carboplatin

Study Locations (20)

California

  • Research Site - Bakersfield
  • Research Site - Fullerton
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Redondo Beach
  • Research Site - Sacramento
  • Research Site - San Luis Obispo
  • Research Site - Santa Maria
  • Research Site - West Hollywood

Arizona

  • Research Site - Scottsdale
  • Research Site - Tucson
  • Research Site - Yuma

Florida

  • Research Site - Jacksonville
  • Research Site - Pembroke Pines
  • Research Site - Tampa

Connecticut

  • Research Site - New Haven

Georgia

  • Research Site - Athens

Hawaii

  • Research Site - Honolulu

Maryland

  • Research Site - Baltimore

Trial Details

FieldValue
Enrollment Target 1,118 participants
Start Date 2015-07-21
Est. Completion 2026-12-31
Phase Phase 3
AstraZeneca

1,285 total trials

What the registry record for NCT02453282 still lists

NCT02453282 is an interventional study that assigns participants to a tested intervention. Its 1,118 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher).

The record links to 1 condition, with Non-Small-Cell Lung Carcinoma NSCLC appearing as the primary indexed condition, and to 5 interventions - of which MEDI4736 (Durvalumab) is the first listed.

NCT02453282 names 20 study sites across 7 states, led by California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT02453282 about?

NCT02453282 is a clinical study titled "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (E...

What is the current status of trial NCT02453282?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,118 participants. The study started on 2015-07-21. Estimated completion is 2026-12-31.

What conditions does trial NCT02453282 study?

This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma NSCLC.

What interventions are being tested in trial NCT02453282?

The interventions under investigation include: MEDI4736 (Durvalumab) (BIOLOGICAL), MEDI4736 (Durvalumab)+Tremelimumab (BIOLOGICAL), Paclitaxel + Carboplatin (DRUG), Gemcitabine + Cisplatin (DRUG), Gemcitabine + Carboplatin (DRUG).

Who is sponsoring clinical trial NCT02453282?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02453282 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small-Cell Lung Carcinoma NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02453282's enrollment target sits among peer trials

1,118 249th of 2000 higher than 1,751 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02140255 · 1,120 participants · Phase 1

    Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

  • NCT06618534 · 1,120 participants · Phase 2

    Azithromycin for Meningococcal Carriage

  • NCT07164131 · 1,120 participants · Phase 4

    Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams

  • NCT05691478 · 1,122 participants · Phase 2

    A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02453282, the US trial registry maintained by the National Library of Medicine. NCT02453282 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.